Introduction
Activity of the hypothalamo-pituitary adrenal (HPA) axis is altered by obesity and caloric deprivation. Leptin, the protein product of the Lep (obese) gene, is released into the circulation from adipose tissue and regulates food intake, energy expenditure and the HPA axis in part, via the hypothalamus (1) (2) (3) (4) . Leptin influences hypothalamic neurons via the long variant isoform of the leptin receptor, Ob-Rb (1;5;6).
The effects of leptin on the HPA axis are complex. The Ob-Rb is abundant on corticotropin-releasing hormone (CRH) neurons in the parvocellular region of the paraventricular nucleus (PVN) (7) . It has been reported that administration of anti-CRH antibodies or the CRH receptor antagonist alpha-helical CRH (α-hCRH ) inhibits the anorectic effects of leptin (8;9) . These authors suggest that leptin partially regulates energy balance via hypothalamic CRH.
However, leptin has also been reported to have an inhibitory effect on the HPA axis.
Leptin deficient (ob/ob) mice are hypercorticosteronemic (10) . Administration of leptin to fasted rodents (11) , ob/ob mice (11) or immobilization-stressed rodents (12) inhibits plasma ACTH and corticosterone levels. In addition, CRH mRNA expression in the PVN is increased in fasted rats, which have low circulating levels of leptin and ob/ob mice, in which leptin is absent (11;12) . This apparent inverse relationship between plasma leptin and plasma corticosterone appears to support the hypothesis that leptin inhibits the HPA axis (11) . However, recent publications suggest that leptin can stimulate the HPA axis under certain circumstances. Intracerebroventricular (ICV) administration of leptin has been shown to stimulate corticosterone secretion at the onset of the dark phase (13) . In addition, a single ICV injection of leptin in the early light phase has shown to dosedependently increase plasma ACTH and corticosterone secretion (14) . ICV injection of leptin also increases the expression of CRH and its receptor, CRH-R 2 in the PVN (15) .
Leptin may therefore have both inhibitory and stimulatory roles in the regulation of the HPA axis. The mechanism by which leptin interacts with the HPA axis is currently unknown.
Neuromedin U (NMU) is a gastrointestinal and central nervous system (CNS) peptide which has been reported to reduce food intake (16;17) , activate the sympathetic nervous system (18) and increase energy expenditure (17;19) . These effects are similar to those observed following leptin administration (20) (21) (22) . NMU also potently stimulates the HPA axis and induces stress-related behaviors (16) . Within the hypothalamus, NMU mRNA is predominately expressed in the arcuate, suprachiasmatic and dorsomedial nuclei (17;23), which also express the Ob-Rb (24) . NMU immunoreactive fibers project to the PVN (25) .
ICV or intra-PVN administration of NMU to rats significantly increases plasma ACTH and corticosterone (16;26) . Incubation of ex-vivo hypothalamic explants with NMU significantly increases the release of CRH (16) . The effects of NMU on the HPA axis are thought to be mediated via the NMU 2 receptor (NMU2R) (16) , which is expressed in the ependymal layer of the third ventricle, the PVN (17;19;23;27;28) and the arcuate nucleus (23) .
NMU mRNA expression in the arcuate nucleus is reduced following a 48 hour fast, when leptin concentrations are low, and reduced in ob/ob mice, where leptin is absent (17) .
Incubation of ex-vivo hypothalamic explants with leptin increases the release of NMU in vitro (16) . However there is little other published data on the interaction between leptin and NMU systems with regards to regulation of the HPA axis.
Here we investigate the hypothesis that hypothalamic NMU in part mediates the leptininduced activation of the HPA axis by using an anti-NMU immunoglobulin G (anti-NMU IgG) to block endogenous NMU signaling. We have also used anti-NMU IgG to investigate the role of endogenous hypothalamic NMU in the normal diurnal rise in plasma corticosterone.
METHODS AND MATERIALS

Animals
Male Wistar rats (specific pathogen free; Charles River, Margate, UK), weighing 200-250 g, were maintained in individual cages under controlled temperature (21-23 C) and light (12 h light/dark cycle, lights on at 0700 h) with ad libitum access to food (RM1 diet, SDS UK Ltd. Witham, UK), unless otherwise described. Food intake and body weight were measured daily throughout the study and all rats were handled daily to habituate and minimize any stress. All animal experimentation was conducted in accordance with accepted standards of humane animal care and carried out under the 1986 British Animals (Scientific Procedures) Act, License number 70/5516.
Materials
Recombinant murine leptin was a gift from M. Chiesi and N. Levens of Novartis (Basel, Switzerland). Reagents for the ex-vivo hypothalamic explant experiments were supplied by BDH (Poole, Dorset, UK). All peptides were reconstituted at the beginning of each study in vehicle (non-immune rabbit serum (NIRS)).
Antibody purification
The anti-NMU IgG was produced and purified using methods previously described (29;30) .
Intracerebroventricular (ICV) cannulation and injection
Animal surgical procedures and handling were carried out as previously described (30) .
All compounds were injected using a 27 gauge stainless steel injector placed in and projecting 1mm below the tip of the cannula. Cannula placement was confirmed by a positive dipsogenic response to angiotensin II (150ng). Only those animals showing a positive dipsogenic response were included in the data analysis (>98%). All animals were habituated to the injection process by a subsequent saline injection.
Leptin and immunoblockade of leptin by anti-NMU IgG on hypothalamic CRH release
A static incubation system was used as described previously (16) . Briefly, ad libitum fed male Wistar rats were killed by decapitation and the whole brain immediately removed. The tubes were placed on a platform in a water bath maintained at 37 C. After an initial 2 hour equilibration period, the hypothalami were incubated for 45 minutes in 600µl aCSF 
Radioimmunoassays (RIA)
CRH-immunoreactivity (IR) and NMU-IR were measured using established assays (16).
The intra-and inter-assay variations of both assays were less that 10%. Plasma corticosterone (MP Biomedicals, Hampshire, UK) and leptin (Linco Research Inc., St.
Louis, MO) levels were measured using commercially available RIA kits. The intra-and inter-assay coefficients of variation for plasma corticosterone were less than 10%. Plasma ACTH (IDS Ltd, Tyne and Wear, UK) was measured by IRMA. The intra-and inter-assay coefficients of variation for ACTH were less than 4%.
Statistical analysis
Data are presented as mean ± sem. Data from ex-vivo hypothalamic explant release experiments were compared by paired t-test between the basal period and the test period.
For the ICV studies, groups were compared by one-way ANOVA followed by a post-hoc (Figure 2A and B) . Anti-NMU IgG alone had no effect on plasma ACTH or corticosterone [plasma ACTH (pg/ml): anti-NMU IgG, 74 ± 27; plasma corticosterone (ng/ml): anti-NMU IgG, 312 ± 38] (Figure 2A and B) . Hypothalamic NMU mRNA expression showed a diurnal rhythm with levels peaking at 2300 h, 4 hours after lights off ( Figure 3A) . Hypothalamic NMU peptide content displayed a diurnal variation reaching a nadir at 1100 h, 4 hours after lights on. NMU peptide content subsequently increased throughout the day peaking at the onset of the dark phase (1900 h) ( Figure 3B ). Hypothalamic NMU mRNA expression was positively correlated with NMU peptide content (r 2 = 0.514, p < 0.02).
As expected, plasma corticosterone displayed a diurnal variation, with levels rising towards the end of the light phase (1700 h) and peaking at 2100 h ( Figure 3A) . A similar diurnal pattern existed between plasma corticosterone and hypothalamic NMU peptide.
However, this correlation did not achieve statistical significance (r 2 = 0.303, p = 0.062).
Plasma leptin exhibited a diurnal pattern, reaching a nadir at 1100 h, 4 hours after lights on. Plasma leptin began to rise at the onset of the dark phase (1900 h) and peaked at 2100 h ( Figure 3C ). Plasma leptin levels were positively correlated with hypothalamic NMU mRNA expression (r 2 = 0.321, p < 0.05) and peptide content (r 2 = 0.588, p < 0.01) (see
Supplemental figures for regression plots).
The effect of peripheral leptin on hypothalamic NMU mRNA and peptide expression.
A single i.p. injection of leptin had no effect on hypothalamic NMU mRNA expression 
Discussion
The evidence for the role of leptin in the regulation of the HPA axis is conflicting. Models of leptin deficiency suggest leptin inhibits the HPA axis (11;35) and leptin administration has been reported to suppress HPA axis activity (12;36) . However, there is also evidence that leptin can stimulate the HPA axis (13) (14) (15) . These current studies suggest that leptin stimulates the release of CRH from ex-vivo hypothalamic explants. This is in accord with studies showing that leptin increases CRH release, peptide concentration and mRNA expression in the PVN (14;37). In our current experiments, ICV administration of leptin increased plasma ACTH and corticosterone 20 minutes post injection, in agreement with published data (14) . Leptin therefore appears to stimulate the HPA axis via the release of CRH under these specific conditions. A number of hypothalamic circuits are thought to regulate different aspects of "stress" and HPA axis activation. It is therefore quite possible that leptin can play both stimulatory and inhibitory roles in the regulation of the neuroendocrine response to stress. For example, both neuropeptide Y (NPY) and CRH neurons are leptin responsive, although leptin inhibits NPY release whilst stimulating CRH (1) . Both of these neuropeptides stimulate the HPA axis but may be differentially regulated by different types of stress (13) .
Hypothalamic release of NMU from ex-vivo hypothalamic explants is stimulated by leptin 
